Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zanidatamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zanidatamab overview

Zanidatamab is under development for the treatment of HER2-expressing cancers such as salivary gland cancer, endometrial cancer, biliary tract cancer, fallopian tube cancer, cervical cancer, gall bladder cancer, cholangiocarcinoma, bile duct cancer (cholangiocarcinoma), metastatic breast cancer (HER2-positive and HR positive), metastatic ovarian cancer, non-small cell lung cancer, gastric and gastroesophageal junction carcinomas, gastroesophageal junction, adenocarcinoma of the gastroesophageal junction, esophageal adenocarcinomas and metastatic colorectal cancer. It is administered intravenously. ZW-25 is a humanized bi-specific monoclonal antibody targeting the extracellular domain of HER2. The drug candidate is based on Azymetric technology.

It was also under development for adnexal carcinoma of skin.

Jazz Pharmaceuticals overview

Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Defitelio (defibrotide sodium), Erwinaze (asparaginase erwinia chrysanthemi), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

For a complete picture of Zanidatamab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.